These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 30025882)

  • 1. Neoadjuvant Chemotherapy Reinforces Antitumour T cell Response in Urothelial Urinary Bladder Cancer.
    Krantz D; Hartana CA; Winerdal ME; Johansson M; Alamdari F; Jakubczyk T; Huge Y; Aljabery F; Palmqvist K; Zirakzadeh AA; Holmström B; Riklund K; Sherif A; Winqvist O
    Eur Urol; 2018 Dec; 74(6):688-692. PubMed ID: 30025882
    [TBL] [Abstract][Full Text] [Related]  

  • 2. IL-16 processing in sentinel node regulatory T cells is a factor in bladder cancer immunity.
    Krantz D; Mints M; Winerdal M; Riklund K; Rutishauser D; Zubarev R; Zirakhzadeh AA; Alamdari F; Johansson M; Sherif A; Winqvist O
    Scand J Immunol; 2020 Dec; 92(6):e12926. PubMed ID: 32862475
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pathologic downstaging is a surrogate marker for efficacy and increased survival following neoadjuvant chemotherapy and radical cystectomy for muscle-invasive urothelial bladder cancer.
    Rosenblatt R; Sherif A; Rintala E; Wahlqvist R; Ullén A; Nilsson S; Malmström PU;
    Eur Urol; 2012 Jun; 61(6):1229-38. PubMed ID: 22189383
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tumor regression grade of urothelial bladder cancer after neoadjuvant chemotherapy: a novel and successful strategy to predict survival.
    Fleischmann A; Thalmann GN; Perren A; Seiler R
    Am J Surg Pathol; 2014 Mar; 38(3):325-32. PubMed ID: 24525502
    [TBL] [Abstract][Full Text] [Related]  

  • 5. TOX-expressing terminally exhausted tumor-infiltrating CD8
    Han HS; Jeong S; Kim H; Kim HD; Kim AR; Kwon M; Park SH; Woo CG; Kim HK; Lee KH; Seo SP; Kang HW; Kim WT; Kim WJ; Yun SJ; Shin EC
    Cancer Lett; 2021 Feb; 499():137-147. PubMed ID: 33249194
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tumour-draining axillary lymph nodes in patients with large and locally advanced breast cancers undergoing neoadjuvant chemotherapy (NAC): the crucial contribution of immune cells (effector, regulatory) and cytokines (Th1, Th2) to immune-mediated tumour cell death induced by NAC.
    Kaewkangsadan V; Verma C; Eremin JM; Cowley G; Ilyas M; Eremin O
    BMC Cancer; 2018 Feb; 18(1):123. PubMed ID: 29390966
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sentinel node detection in muscle-invasive urothelial bladder cancer is feasible after neoadjuvant chemotherapy in all pT stages, a prospective multicenter report.
    Rosenblatt R; Johansson M; Alamdari F; Sidiki A; Holmström B; Hansson J; Vasko J; Marits P; Gabrielsson S; Riklund K; Winqvist O; Sherif A
    World J Urol; 2017 Jun; 35(6):921-927. PubMed ID: 27738804
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Standard or accelerated methotrexate, vinblastine, doxorubicin and cisplatin as neoadjuvant chemotherapy for locally advanced urothelial bladder cancer: Does dose intensity matter?
    Pouessel D; Chevret S; Rolland F; Gravis G; Geoffrois L; Roubaud G; Terrisse S; Boyle H; Chevreau C; Dauba J; Moriceau G; Alexandre I; Deplanque G; Chapelle A; Vauleon E; Colau A; Audenet F; Grellety T; Culine S
    Eur J Cancer; 2016 Feb; 54():69-74. PubMed ID: 26724422
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Cancer Immunogram as a Framework for Personalized Immunotherapy in Urothelial Cancer.
    van Dijk N; Funt SA; Blank CU; Powles T; Rosenberg JE; van der Heijden MS
    Eur Urol; 2019 Mar; 75(3):435-444. PubMed ID: 30274701
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Fewer tumour draining sentinel nodes in patients with progressing muscle invasive bladder cancer, after neoadjuvant chemotherapy and radical cystectomy.
    Alvaeus J; Rosenblatt R; Johansson M; Alamdari F; Jakubczyk T; Holmström B; Hemdan T; Huge Y; Aljabery F; Gabrielsson S; Riklund K; Winqvist O; Sherif A
    World J Urol; 2020 Sep; 38(9):2207-2213. PubMed ID: 31760442
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Increased CD4
    Ahlén Bergman E; Hartana CA; Johansson M; Linton LB; Berglund S; Hyllienmark M; Lundgren C; Holmström B; Palmqvist K; Hansson J; Alamdari F; Huge Y; Aljabery F; Riklund K; Winerdal ME; Krantz D; Zirakzadeh AA; Marits P; Sjöholm LK; Sherif A; Winqvist O
    Clin Epigenetics; 2018 Aug; 10(1):102. PubMed ID: 30075815
    [TBL] [Abstract][Full Text] [Related]  

  • 12. ICUD-EAU International Consultation on Bladder Cancer 2012: Chemotherapy for urothelial carcinoma-neoadjuvant and adjuvant settings.
    Sternberg CN; Bellmunt J; Sonpavde G; Siefker-Radtke AO; Stadler WM; Bajorin DF; Dreicer R; George DJ; Milowsky MI; Theodorescu D; Vaughn DJ; Galsky MD; Soloway MS; Quinn DI;
    Eur Urol; 2013 Jan; 63(1):58-66. PubMed ID: 22917984
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [ypT0N0 after neoadjuvant chemotherapy and cystectomy for muscle-invasive bladder cancer: Incidence and prognosis. A review from the Bladder group of the French Committee of Oncology].
    Pignot G; Houédé N; Roumiguié M; Audenet F; Brunelle S; Colin P; Compérat E; Larré S; Masson-Lecomte A; Neuzillet Y; Xylinas E; Méjean A; Rouprêt M;
    Prog Urol; 2018 Oct; 28(12):567-574. PubMed ID: 30205925
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Association between the Absolute Baseline Lymphocyte Count and Response to Neoadjuvant Platinum-based Chemotherapy in Muscle-invasive Bladder Cancer.
    Leibowitz-Amit R; Israel A; Gal M; Atenafu EA; Symon Z; Portnoy O; Laufer M; Dotan Z; Ramon J; Avni D; Fridman E; Berger R
    Clin Oncol (R Coll Radiol); 2016 Dec; 28(12):790-796. PubMed ID: 27498850
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Modified spatial architecture of regulatory T cells after neoadjuvant chemotherapy in non-small cell lung cancer patients.
    Cai S; Zhao M; Yang G; Li C; Hu M; Yang L; Xing L; Sun X
    Int Immunopharmacol; 2024 Aug; 137():112434. PubMed ID: 38889507
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Outside the box of immunotherapy - new hope for patients with advanced urothelial cancer.
    Ullén A
    Acta Oncol; 2019 Jul; 58(7):951-952. PubMed ID: 31232133
    [No Abstract]   [Full Text] [Related]  

  • 17. Crucial Contributions by T Lymphocytes (Effector, Regulatory, and Checkpoint Inhibitor) and Cytokines (TH1, TH2, and TH17) to a Pathological Complete Response Induced by Neoadjuvant Chemotherapy in Women with Breast Cancer.
    Kaewkangsadan V; Verma C; Eremin JM; Cowley G; Ilyas M; Eremin O
    J Immunol Res; 2016; 2016():4757405. PubMed ID: 27777963
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CD103+ Tumor Infiltrating Lymphocytes Predict a Favorable Prognosis in Urothelial Cell Carcinoma of the Bladder.
    Wang B; Wu S; Zeng H; Liu Z; Dong W; He W; Chen X; Dong X; Zheng L; Lin T; Huang J
    J Urol; 2015 Aug; 194(2):556-62. PubMed ID: 25752441
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clonal expansion of antitumor T cells in breast cancer correlates with response to neoadjuvant chemotherapy.
    Park JH; Jang M; Tarhan YE; Katagiri T; Sasa M; Miyoshi Y; Kalari KR; Suman VJ; Weinshilboum R; Wang L; Boughey JC; Goetz MP; Nakamura Y
    Int J Oncol; 2016 Aug; 49(2):471-8. PubMed ID: 27278091
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tumour-infiltrating lymphocytes and prognosis in different subtypes of breast cancer: a pooled analysis of 3771 patients treated with neoadjuvant therapy.
    Denkert C; von Minckwitz G; Darb-Esfahani S; Lederer B; Heppner BI; Weber KE; Budczies J; Huober J; Klauschen F; Furlanetto J; Schmitt WD; Blohmer JU; Karn T; Pfitzner BM; Kümmel S; Engels K; Schneeweiss A; Hartmann A; Noske A; Fasching PA; Jackisch C; van Mackelenbergh M; Sinn P; Schem C; Hanusch C; Untch M; Loibl S
    Lancet Oncol; 2018 Jan; 19(1):40-50. PubMed ID: 29233559
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.